Alivus Life Sciences (NSE:ALIVUS) Construction In Progress: ₹2,734 Mil (As of Mar. 2026)


NSE:ALIVUS Alivus Life Sciences Ltd NSE:ALIVUS
84 GF Score
Price ₹1,156.50
GF Value ₹1,012.74
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alivus Life Sciences Construction In Progress?

Alivus Life Sciences NSE:ALIVUS +3.31% 84 Construction In Progress is ₹2,734 Mil as of Mar. 2026. GuruFocus rates NSE:ALIVUS with a GF Score™ of 84/100 and a GF Value™ of ₹1,012.74 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Alivus Life Sciences's quarterly construction in progress declined from Sep. 2025 (₹1,728 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹2,734 Mil).

Alivus Life Sciences's annual construction in progress declined from Mar. 2024 (₹1,098 Mil) to Mar. 2025 (₹1,031 Mil) but then increased from Mar. 2025 (₹1,031 Mil) to Mar. 2026 (₹2,734 Mil).

Alivus Life Sciences Construction In Progress Historical Data

* Premium members only.

The historical data trend for Alivus Life Sciences's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alivus Life Sciences Construction In Progress Chart

Alivus Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Construction In Progress
Get a 7-Day Free Trial 1,057.58 506.26 1,097.69 1,030.53 2,734.04

Alivus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,030.53 0.00 1,728.00 0.00 2,734.04
NSE:ALIVUS
84GF Score
Alivus Life Sciences Ltd NSE:ALIVUS
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alivus Life Sciences Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ₹2,734 Mil mean?
Alivus Life Sciences (NSE:ALIVUS) has a Construction In Progress of ₹2,734 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Alivus Life Sciences and its competitors.
Is Alivus Life Sciences' Construction In Progress too high?
Alivus Life Sciences' current Construction In Progress is ₹2,734 Mil. Overall, Alivus Life Sciences has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Construction In Progress compare to ZTS and UTHR?
Alivus Life Sciences' Construction In Progress of ₹2,734 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Alivus Life Sciences and its competitors. Alivus Life Sciences's current Construction In Progress is ₹2,734 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,012.74, compared to a current price of ₹1,156.50 — trading 14.2% above its estimated fair value. The current Construction In Progress is ₹2,734 Mil. Alivus Life Sciences' overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Construction In Progress is ₹2,734 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?

Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued. The current stock price of ₹1,156.50 is trading 14.2% above its estimated GF Value™ of ₹1,012.74. GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.

Key valuation signals for NSE:ALIVUS:

  • Construction In Progress: ₹2,734 Mil
  • GF Value™: ₹1,012.74 vs. price of ₹1,156.50 (14.2% above fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alivus Life Sciences Business Description

Other Exchanges 543322:India
Address 470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
84GF Score

Get the complete analysis for NSE:ALIVUS

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,156.50
Price
₹1,012.74
GF Value